Systemic Inflammatory Response Syndrome and Prosthetic Joint Infection
Copyright © 2023 Elsevier Inc. All rights reserved..
BACKGROUND: The development of systemic inflammatory response syndrome (SIRS) criteria leads to increased mortality. Little is known about development of SIRS in patients who have prosthetic joint infection (PJI). We aimed to determine the incidence, risk factors, clinical outcomes, and causative organisms in patients who develop SIRS with PJI.
METHODS: We retrospectively identified 655 patients (321 men, 334 women; 382 total hip, 273 total knee) who have hip or knee PJI at 1 institution between July 1, 2015 and December 31, 2020. We formed 2 groups: patients who have SIRS alert (PJI + SIRS) and patients who do not have SIRS alert (PJI). We analyzed clinical outcomes, comorbidities, and operating room culture results.
RESULTS: Of 655 patients, 63 developed SIRS with PJI (9.6%). Intensive care unit (ICU) admission rates (27.0 versus. 6.9%, P < .001) and length of stay (7.7 versus. 5.6 days, P = .003) were greater in PJI + SIRS. At 2 years, reoperation (36.5 versus. 22.3%, P = .01) and mortality rates (17.5 versus. 8.8%, P = .03) were greater in PJI + SIRS. Risk factors included deficiency anemia (P = .001), blood loss anemia (P = .013), uncomplicated diabetes (P = .006), diabetes with complication (P = .001), electrolyte disorder (P < .00001), neurological disorder (P = .0001), paralysis (P = .026), renal failure (P = .005), and peptic ulcer disease (P = .004). Staphylococcus aureus more commonly speciated on tissue cultures in PJI + SIRS (P = .002).
CONCLUSION: The incidence of SIRS is 10% among patients who have PJI. Development of PJI + SIRS is associated with increased lengths of stay, ICU admissions, and 2-year reoperation and mortality rates. Identifying certain comorbidities can stratify patients' risk of developing PJI + SIRS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
The Journal of arthroplasty - 39(2023), 1 vom: 01. Jan., Seite 236-241 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
McConnell, Zachary A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical outcomes |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 04.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.arth.2023.07.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360317294 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360317294 | ||
| 003 | DE-627 | ||
| 005 | 20231226082748.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.arth.2023.07.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360317294 | ||
| 035 | |a (NLM)37531981 | ||
| 035 | |a (PII)S0883-5403(23)00785-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a McConnell, Zachary A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Systemic Inflammatory Response Syndrome and Prosthetic Joint Infection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 04.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: The development of systemic inflammatory response syndrome (SIRS) criteria leads to increased mortality. Little is known about development of SIRS in patients who have prosthetic joint infection (PJI). We aimed to determine the incidence, risk factors, clinical outcomes, and causative organisms in patients who develop SIRS with PJI | ||
| 520 | |a METHODS: We retrospectively identified 655 patients (321 men, 334 women; 382 total hip, 273 total knee) who have hip or knee PJI at 1 institution between July 1, 2015 and December 31, 2020. We formed 2 groups: patients who have SIRS alert (PJI + SIRS) and patients who do not have SIRS alert (PJI). We analyzed clinical outcomes, comorbidities, and operating room culture results | ||
| 520 | |a RESULTS: Of 655 patients, 63 developed SIRS with PJI (9.6%). Intensive care unit (ICU) admission rates (27.0 versus. 6.9%, P < .001) and length of stay (7.7 versus. 5.6 days, P = .003) were greater in PJI + SIRS. At 2 years, reoperation (36.5 versus. 22.3%, P = .01) and mortality rates (17.5 versus. 8.8%, P = .03) were greater in PJI + SIRS. Risk factors included deficiency anemia (P = .001), blood loss anemia (P = .013), uncomplicated diabetes (P = .006), diabetes with complication (P = .001), electrolyte disorder (P < .00001), neurological disorder (P = .0001), paralysis (P = .026), renal failure (P = .005), and peptic ulcer disease (P = .004). Staphylococcus aureus more commonly speciated on tissue cultures in PJI + SIRS (P = .002) | ||
| 520 | |a CONCLUSION: The incidence of SIRS is 10% among patients who have PJI. Development of PJI + SIRS is associated with increased lengths of stay, ICU admissions, and 2-year reoperation and mortality rates. Identifying certain comorbidities can stratify patients' risk of developing PJI + SIRS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a clinical outcomes | |
| 650 | 4 | |a comorbidities | |
| 650 | 4 | |a increased mortality | |
| 650 | 4 | |a operating room culture results | |
| 650 | 4 | |a prosthetic joint infection | |
| 650 | 4 | |a systemic inflammatory response syndrome | |
| 700 | 1 | |a Patel, Karan M |e verfasserin |4 aut | |
| 700 | 1 | |a Mears, Simon C |e verfasserin |4 aut | |
| 700 | 1 | |a Stronach, Benjamin M |e verfasserin |4 aut | |
| 700 | 1 | |a Barnes, C Lowry |e verfasserin |4 aut | |
| 700 | 1 | |a Stambough, Jeffrey B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of arthroplasty |d 1995 |g 39(2023), 1 vom: 01. Jan., Seite 236-241 |w (DE-627)NLM012629375 |x 1532-8406 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:236-241 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.arth.2023.07.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2023 |e 1 |b 01 |c 01 |h 236-241 | ||